Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
Recruiting now
Conditions studied: Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR, ATTR-Mixed, hATTR
In brief
The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.
Key facts
- Study ID
- NCT06465810
- Run by
- AstraZeneca
- People needed
- 1850
- Starts
- 2024-06-25
- Expected to finish
- 2031-12-29
- Last updated by the study team
- 2026-07-28
Who can join
Age: 18 and older, up to 130. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patient willing and able to provide written informed consent to participate in the study
- Confirmed diagnosis of amyloid transthyretin (ATTR) amyloidosis
- Aged ≥18 years at the time of signing the informed consent
- Patient willing and able to participate in collection of electronic patient reported outcomes (PROs)
You may not qualify if…
- Concurrent participation in any interventional trial for ATTR amyloidosis
- Involvement in the planning and/or conduct of the current study
- Patients with evidence of primary or light chain amyloidosis (AL) or serum protein A amyloidosis (AA)
- Asymptomatic patients with ATTR amyloidosis and asymptomatic ATTR mutation carriers
Where it is running
- Research Site — Frankfurt am Main, Hesse, Germany (enrolling)
- Research Site — Mainz, Rhineland-Palatinate, Germany (enrolling)
- Research Site — Shanghai, Shanghai Municipality, China (enrolling)
- Research Site — Shaanxi, Xi'An, China (enrolling)
- Research Site — Aachen, North Rhine-Westphalia, Germany (enrolling)
- Research Site — Cologne, North Rhine-Westphalia, Germany (enrolling)
- Research Site — Vancouver, British Columbia, Canada (enrolling)
- Research Site — Beijing, Beijing Municipality, China (enrolling)
- Research Site — Halifax, Nova Scotia, Canada (enrolling)
- Research Site — Chengdu, Sichuan, China (enrolling)
- Research Site — Hanover, Lower Saxony, Germany (enrolling)
- Research Site — Guangzhou, Guangdong, China (enrolling)
- Research Site — Guangzhou, Guangdong, China (enrolling)
- Research Site — Beijing, Beijing Municipality, China (enrolling)
- Research Site — Beijing, Beijing Municipality, China (enrolling)
- Research Site — Toronto, Ontario, Canada (enrolling)
- Research Site — Wuhan, Hubei, China (enrolling)
- Research Site — Changsha, Hunan, China (enrolling)
- Research Site — Nanjing, Jiangsu, China (enrolling)
- Research Site — Beijing, Beijing Municipality, China (enrolling)
- Research Site — Nanchang, Jiangxi, China (enrolling)
- Research Site — Chongqing, Chongqing Municipality, China (enrolling)
- Research Site — Jinan, Shandong, China (enrolling)
- Research Site — London, Ontario, Canada (enrolling)
- Research Site — Homburg, Saarland, Germany (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.